GeneDx Holdings Corp. revenue by segment WGS

Annual Quarterly

GeneDx Holdings Corp. splits its revenue into 5 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Diagnostic Test Third Party Insurance at $94.7 million, 83% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	454	114	102	121	117	103	87	96	77
Diagnostic Test	—	—	—	117 +24.5% share 96.9%	114 +46.6% share 97.2%	—	—	94 share 98.5%	77 share 100.7%
Diagnostic Test Third Party Insurance	376 +30.7% share 82.7%	95 +16.8% share 82.8%	85 +24.8% share 83.0%	101 +28.1% share 83.5%	95 +60.3% share 81.4%	81 share 79.0%	68 share 78.1%	79 share 82.5%	59 share 77.1%
Diagnostic Test Institutional Customers	65 -4.4% share 14.3%	16 -13.6% share 14.1%	16 -11.8% share 15.2%	16 +8.3% share 12.8%	18 +0.7% share 15.0%	19 share 18.2%	18 share 20.2%	14 share 15.0%	17 share 22.7%
Product And Service Other	10 +115.2% share 2.3%	3 -1.5% share 2.2%	1 -29.6% share 0.9%	4 +156.4% share 3.1%	3 +691.9% share 2.8%	3 share 2.5%	1 share 1.6%	1 share 1.5%	-1 share -0.7%
Diagnostic Test Self Pay	2 +50.8% share 0.5%	1 +207.4% share 0.9%	0 +197.9% share 0.3%	0 -50.5% share 0.2%	1 +36.7% share 0.5%	0 share 0.3%	0 share 0.1%	1 share 0.6%	0 share 0.6%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Services-Health Services (SIC 8000)
Listed as: WGS (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Stamford, CT
SEC filer status: Large accelerated filer
SEC CIK: 1818331
Former names: Sema4 Holdings Corp. (until Jan 5, 2023); CM Life Sciences, Inc. (until Jul 21, 2021)

Other Services-Health Services companies

All 17 Services-Health Services companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.